Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer.

Akbiyik, Ilgin; Ürün, Yüksel

Akbiyik, Ilgin; Ürün, Yüksel.

Affiliation

Akbiyik I; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Ürün Y; Ankara University Cancer Research Institute, Ankara, Turkey.

Future Oncol ; 19(39): 2585-2591, 2023 Dec.

Article in En | MEDLINE | ID: mdl-38073492

Subject(s)

Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Male; Humans; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use; Prostatic Neoplasms, Castration-Resistant/drug therapy; Prostatic Neoplasms, Castration-Resistant/genetics; Mutation; Biomarkers

Key words

BRCA1; BRCA2; DNA damage repair; PARP inhibitors; castration-resistant; homologous recombination repair; prostate cancer

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Poly(ADP-ribose) Polymerase Inhibitors Limits: Humans / Male Language: En Journal: Future Oncol Year: 2023 Type: Article Affiliation country: Turkey

Fulltext

XML

PubMed Links

Search on Google